Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | STAT1 | P42224 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508553 | 0.82 | TSHR (0.55) | HPGDKMT2ASMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL11612820 | 0.82 | HDAC8 (0.42) | LMNARAB9AKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL182327 | 0.81 | CYP2C9 (0.55) | MAPTHPGDLMNARAB9AL3MBTL1 | |
| SCHEMBL9683939 | 0.81 | MAPT (0.50) | MAPTHPGDLMNARAB9AL3MBTL1 | |
| SCHEMBL10365027 | 0.81 | CYP2A6 (0.49) | MAPTHPGDLMNARAB9AKMT2A | |
| SCHEMBL27300787 | 0.80 | PARP10 (0.52) | MAPTL3MBTL1KMT2ASMN1; SMN2NOS1 | |
| Bromide SCHEMBL27719616 | 0.80 | TSHR (0.52) | HPGDKMT2ASMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL1597293 | 0.80 | ALDH1A1 (0.41) | HPGDLMNARAB9AL3MBTL1KMT2A | |
| SCHEMBL1262317 | 0.79 | MAPT (0.48) | MAPTHPGDLMNARAB9AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL5197216 | 0.79 | CYP2C9 (0.53) | MAPTHPGDLMNARAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9701626-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160009639-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS INC (US) | 2016-01-14 | — | — | US | disclosed |
| US-9169201-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140135400-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-1619211-B1 | PROCESS FOR PRODUCTION OF LIVING-RADICAL POLYMERS AND POLYMERS | OTSUKA CHEMICAL CO LTD (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-20120214769-A1 | Novel Antagonists of the Glucagon Receptor | METABASIS THERAPEUTICS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8114629-B2 | Site specific incorporation of keto amino acids into proteins | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110318806-A1 | SITE SPECIFIC INCORPORATION OF KETO AMINO ACIDS INTO PROTEINS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-29 | — | — | US | disclosed |
| US-8071344-B2 | Biosynthesis; orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-06 | — | — | US | disclosed |
| EP-1541550-A1 | ORGANIC TELLURIUM COMPOUND, PROCESS FOR PRODUCING THE SAME, LIVING RADICAL POLYMERIZATION INITIATOR, PROCESS FOR PRODUCING POLYMER WITH THE SAME, AND POLYMER | Otsuka Chemical Co., Ltd. (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1541592-A1 | PROCESS FOR PRODUCTION OF LIVING RADICAL POLYMERS AND POLYMERS | OTSUKA CHEMICAL COMPANY, LIMITED (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1534703-A2 | ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR | ABBOTT LABORATORIES (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040198637-A1 | Polypeptide incorporating unnatural amino acid chemically bonded to solid support by a chemical linkage | THE SCRIPPS RESEARCH INSTITUTE | 2004-10-07 | — | — | US | disclosed |
| WO-2004058946-A2 | PROTEIN ARRAYS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040138106-A1 | Glycoprotein synthesis | THE SCRIPPS RESEARCH INSTITUTE | 2004-07-15 | — | — | US | disclosed |
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004035743-A2 | SITE SPECIFIC INCORPORATION OF KETO AMINO ACIDS INTO PROTEINS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035605-A2 | GLYCOPROTEIN SYNTHESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003106452-A2 | ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009639-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | MAPT 3346/4885HPGD 2678/4885LMNA 2993/4885 |
| US-20040138106-A1 | Glycoprotein synthesis | UGGT1, ST6GAL1, ANPEP | MAPT 4105/4885HPGD 1907/4885LMNA 3304/4885 |
| US-20140135400-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | MAPT 3346/4885HPGD 2678/4885LMNA 2993/4885 |
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | MAPT 4185/4885HPGD 1048/4885LMNA 3781/4885 |
| US-20120214769-A1 | Novel Antagonists of the Glucagon Receptor | GLP1R, GCGR, GPR119 | MAPT 3346/4885HPGD 2678/4885LMNA 2993/4885 |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | MAPT 3346/4885HPGD 2678/4885LMNA 2993/4885 |
| US-20040198637-A1 | Polypeptide incorporating unnatural amino acid chemically bonded to solid support by a chemical linkage | DNPEP, NPEPPS, ANPEP | MAPT 2216/4885HPGD 3848/4885LMNA 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.